Literature DB >> 6333258

Efficient transformation of previously activated and dividing T lymphocytes by human T cell leukemia-lymphoma virus.

S Merl, B Kloster, J Moore, C Hubbell, R Tomar, F Davey, D Kalinowski, A Planas, G Ehrlich, D Clark.   

Abstract

Modifying previously reported techniques, we attempted to increase the efficiency of human T cell leukemia-lymphoma virus (HTLV) transformation of human T lymphocytes. Lethally irradiated donor cells (DCs) were cultured with target mononuclear cells (TMCs). DCs included ten HTLV+ T cell lines with varying degrees of virus expression or seven cell lines that do not express HTLV. TMCs were prepared from 20 cord and 16 adult peripheral blood samples, including eight patients with acquired immunodeficiency syndrome (AIDS). TMCs were either added directly to the DCs or were first stimulated with phytohemagglutinin (PHA) (5 micrograms/mL) and grown in T cell growth factor (TCGF) prior to exposure to DCs. The presence of integrated HTLV proviral DNA in the transformed cells was determined by dot blot hybridization, utilizing a cloned probe to the HTLV-I genome. HTLV production by transformed TMCs was assessed for HTLV p19, reverse transcriptase, and virus particles. No transformation occurred with T cell donor lines that do not express HTLV. Low virus expressor DCs could only, with rare exception, transform preactivated TMCs. High-titer virus-producing DCs could transform activated and nonactivated cord blood cells and activated adult TMCs. Only MT-2 could routinely transform nonactivated normal adult and activated AIDS TMCs. HUT 102 B2 could transform only one activated AIDS sample, the cells of which initially expressed HTLV-like proteins and virions. Transformed cell lines contained subsets of mature T lymphocytes with variable HTLV expression. Prior activation and culture of the T lymphocytes increases the probability and rate of transformation by HTLV, allowing for biologic detection of low HTLV-producing cells and for in vitro expansion of T lymphocyte subsets from selected patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333258

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I.

Authors:  N Fan; J Gavalchin; B Paul; K H Wells; M J Lane; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Temporal regulation of viral and cellular gene expression during human T-lymphotropic virus type I-mediated lymphocyte immortalization.

Authors:  J T Kimata; L Ratner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 3.  Viral modulation of T-cell receptor signaling.

Authors:  Keith R Jerome
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

4.  TCF1 and LEF1 act as T-cell intrinsic HTLV-1 antagonists by targeting Tax.

Authors:  Guangyong Ma; Jun-ichirou Yasunaga; Hirofumi Akari; Masao Matsuoka
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

5.  High IgM antibody to human T-lymphotropic virus type I in systemic lupus erythematosus.

Authors:  P E Phillips; S L Johnston; L A Runge; J L Moore; B J Poiesz
Journal:  J Clin Immunol       Date:  1986-05       Impact factor: 8.317

6.  Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein.

Authors:  Omar Haffar; Larisa Dubrovsky; Richard Lowe; Reem Berro; Fatah Kashanchi; Jeffrey Godden; Christophe Vanpouille; Jürgen Bajorath; Michael Bukrinsky
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

7.  Human T-cell lymphotropic virus type 1 p12I enhances interleukin-2 production during T-cell activation.

Authors:  Wei Ding; Seung-Jae Kim; Amrithraj M Nair; Bindhu Michael; Kathleen Boris-Lawrie; Adam Tripp; Gerold Feuer; Michael D Lairmore
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Evolutionary insights on the origin of human T-cell lymphoma/leukemia virus type I (HTLV-I) derived from sequence analysis of a new HTLV-I variant from Papua New Guinea.

Authors:  M P Sherman; N K Saksena; D K Dube; R Yanagihara; B J Poiesz
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Isolation and characterization of simian T-cell leukemia virus type II from New World monkeys.

Authors:  Y M Chen; Y J Jang; P J Kanki; Q C Yu; J J Wang; R J Montali; K P Samuel; T S Papas
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

10.  Genetic heterogeneity in human T-cell leukemia/lymphoma virus type II.

Authors:  D K Dube; M P Sherman; N K Saksena; V Bryz-Gornia; J Mendelson; J Love; C B Arnold; T Spicer; S Dube; J B Glaser
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.